4DMedical Says Study Shows CT:VQ Imaging Product Lifts Lung Surgery Response Rate to 76%; Shares Up 3%
MT Newswires Live
May 19
4DMedical (ASX:4DX) said a study evaluating its CT:VQ imaging product, published in the American Journal of Respiratory and Critical Care Medicine, shows that CT:VQ-guided patient selection would deliver a 76% response rate to lung volume reduction surgery (LVRS), compared with the current rate of 46%, according to a Tuesday Australian bourse filing.
The company said CT:VQ derives functional ventilation and perfusion information from existing non-contrast CT scans, with improved pre-operative patient selection strengthening the economics of LVRS programs for hospitals by concentrating surgical resources on patients most likely to benefit.
The company's shares were up 3% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.